Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Arkansas City, KA
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Arkansas City, KA
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Wichita, KA
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Bardstown, KY
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Metairie, LA
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Omaha, NE
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Cleveland, OH
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Kingsport, TN
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Kingsport, TN
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Austin, TX
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
San Angelo, TX
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
San Angelo, TX
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Orem, UT
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Orem, UT
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Coquitlam,
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Coquitlam,
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Frisco, CA
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Frisco, CA
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Saint Paul, MN
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
S. Jordan, UT
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
S. Jordan, UT
Click here to add this to my saved trials
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Hollywood, FL
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Meridian, ID
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Meridian, ID
Click here to add this to my saved trials
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Lenexa, KA
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Wichita, KA
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Lexington, KY
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Truro,
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Truro,
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Huntsville, AL
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Miami, FL
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Meridian, ID
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Meridian, ID
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Lenexa, KA
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Missoula, MT
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Missoula, MT
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Edison, NJ
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Edison, NJ
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Rochester, NY
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Cleveland, OH
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  11/13/2017
GSK Investigational Site
mi
from
Surrey,
Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 11/13/2017
GSK Investigational Site
mi
from
Surrey,
Click here to add this to my saved trials
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated:  11/16/2017
Optimal Research LLC
mi
from
Huntsville, AL
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated: 11/16/2017
Optimal Research LLC
mi
from
Huntsville, AL
Click here to add this to my saved trials
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated:  11/16/2017
Optimal Research, LLC
mi
from
San Diego, CA
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated: 11/16/2017
Optimal Research, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated:  11/16/2017
Optimal Research, LLC
mi
from
Melbourne, FL
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated: 11/16/2017
Optimal Research, LLC
mi
from
Melbourne, FL
Click here to add this to my saved trials
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated:  11/16/2017
Optimal Research, LLC
mi
from
Peoria, IL
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated: 11/16/2017
Optimal Research, LLC
mi
from
Peoria, IL
Click here to add this to my saved trials
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated:  11/16/2017
Optimal Reserach, LLC
mi
from
Mishawaka, IN
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated: 11/16/2017
Optimal Reserach, LLC
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated:  11/16/2017
Optimal Research, LLC
mi
from
Rockville, MD
Inactivated Influenza Via Jet Injection
Inactivated Influenza Via Jet Injection
Status: Enrolling
Updated: 11/16/2017
Optimal Research, LLC
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Evaluation of Correlates of Protective Efficacy of Seasonal Live Attenuated Influenza Vaccine (LAIV) by Utilization of a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Status: Enrolling
Updated:  11/27/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Evaluation of Correlates of Protective Efficacy of Seasonal Live Attenuated Influenza Vaccine (LAIV) by Utilization of a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Status: Enrolling
Updated: 11/27/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Influenza Vaccine Post Allogeneic Transplant
MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Influenza Vaccine Post Allogeneic Transplant
MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Bardstown, KY
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Metairie, LA
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Miami, FL
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Eunice, LA
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Eunice, LA
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Shelby, NC
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Shelby, NC
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Huntsville, AL
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Coral Gables, FL
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Homestead, FL
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Homestead, FL
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Orlando, FL
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
New Orleans, LA
Study of VIS410 in Subjects With Uncomplicated Influenza A
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials